A 4-week Australian multicentre study of nedocromil sodium in asthmatic patients.
The use of nedocromil sodium 4 mg q.i.d. in asthmatics with mildly unstable asthma induced by a reduction of their inhaled beclomethasone dipropionate dose was investigated in a double-blind, parallel group, placebo-controlled study. Compared with placebo, nedocromil sodium improved night-time and daytime asthma score, night-time and daytime bronchodilator use, and evening PEFR at some stage during the 4-week treatment. It is concluded that nedocromil sodium exerts a beneficial effect in chronic asthma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001315:Australia; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D005540:Forced Expiratory Flow Rates; D006801:Humans; D008875:Middle Aged; D017835:Nedocromil; D011804:Quinolines / Q000627:therapeutic use*; D014797:Vital Capacity
D011804:Quinolines; D017835:Nedocromil